WO1986005981A1 - Treatment of non-ulcer dyspepsia with bismuth salts - Google Patents
Treatment of non-ulcer dyspepsia with bismuth salts Download PDFInfo
- Publication number
- WO1986005981A1 WO1986005981A1 PCT/AU1986/000106 AU8600106W WO8605981A1 WO 1986005981 A1 WO1986005981 A1 WO 1986005981A1 AU 8600106 W AU8600106 W AU 8600106W WO 8605981 A1 WO8605981 A1 WO 8605981A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibiotics
- ulcer dyspepsia
- bismuth salt
- treatment
- antibiotic
- Prior art date
Links
- 201000006549 dyspepsia Diseases 0.000 title claims abstract description 23
- 150000001621 bismuth Chemical class 0.000 title claims abstract description 17
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 8
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 4
- 208000015181 infectious disease Diseases 0.000 claims abstract description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 10
- 229960003022 amoxicillin Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 10
- 230000003115 biocidal effect Effects 0.000 claims description 6
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical group [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 claims description 6
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 5
- 229960005053 tinidazole Drugs 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 3
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 229940072172 tetracycline antibiotic Drugs 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical compound [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 150000001622 bismuth compounds Chemical class 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010015137 Eructation Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000007238 Postcholecystectomy Syndrome Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- -1 nitro-imidazole sulfones Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- Non-ulcer dyspepsia has not been widely recognised in the past as being a single disease process and has been considered as comprising various disorders with such names as "nervous dyspepsia", “irritable bowel syndrome”, “gastritis”, and also "post-cholecystectomy syndrome".
- Non-ulcer dyspepsia is characterised by epigastric discomfort, burning or pain, abdominal distention, bloating, belching or burping, nausea, and frequently it is said that the ingestion of food can precipitate such symptoms.
- the present invention relates to a method of treating non-ulcer dyspepsia in patients suffering from the said non-ulcer dyspepsia, comprising administering to the said patients an effective amount of a pharmaceutically acceptable bismuth salt.
- a preferred bismuth compound for the treatment of non- * ⁇ lcer dyspepsia is tripotassium dicitratobismuthate. This is also known as De-Nol (Registered Trade Mark). Other bismuth compounds known for the treatment of ulcer and other diseases may also be used in the present invention. Ideally, the bismuth salt is administered orally for a period of at least four (4) weeks and may be administered alone in an adequate dose or in combination with other antibiotics.
- antibiotics may be chosen from the classes consisting of ⁇ -lactams, such as penicillins; macrolide antibiotics; tetracycline antibiotics and nitro-imidazole sulfones. From within these classes Amoxycillin, Erythromycin, Tetracycline and Tinidazole have been found to be particularly efficacious.
- Another aspect of the invention comprises a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and pharmaceutieally acceptable carrier or diluent.
- the bismuth salt is tripotassium dicitrato-bismuthate.
- the most preferable antibiotics are selected from the classes specified above.
- the ⁇ -lactam antibiotics Most preferably, the antibiotic is Amoxycillin.
- the pharmaceutical composition is preferably presented in a form suitable for peroral administration, such as liquid, tablet or capsule form.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Treatment of non-ulcer dyspepsia associated with Campylobacter pyloridis infection by the administration of bismuth salts. The administration of bismuth salts in association with antibiotics has been found to be particularly efficacious. A pharmaceutical composition for use in the performance of the present invention is also disclosed.
Description
TREATMENT OF NON-ULCER DYSPEPSIA WITH BISMUTH SALTS BACKGROUND ART This invention relates to a method of treating non-ulcer dyspepsia . In the past bismuth compounds have been used in the treatment of dyspepsia arising from peptic ulcers. However, there has been previously no recognised therapy for the treatment of non-ulcer dyspepsia. Non-ulcer dyspepsia has not been widely recognised in the past as being a single disease process and has been considered as comprising various disorders with such names as "nervous dyspepsia", "irritable bowel syndrome", "gastritis", and also "post-cholecystectomy syndrome". Non-ulcer dyspepsia is characterised by epigastric discomfort, burning or pain, abdominal distention, bloating, belching or burping, nausea, and frequently it is said that the ingestion of food can precipitate such symptoms.
The treatment of this disorder has, until now, been non-specific, empirical and generally inadequate.
It has now been discovered that a new class of sp.iral bacteria reside in the stomach of humans. These bacteria have been found to be closely associated with the presence of gastritis. It has now also been found that the symptoms of non-ulcer dyspepsia are closely related to the presence of the newly discovered spiral bacteria. These bacteria are Campylobacter-like bacteria, currently called Campylobacter pyloridis.
While the use of bismuth salts to treat ulcers has been known, their utility in the treatment of non-ulcer dyspepsia has not been suspected previously. The symptoms of the two conditions are generally different, but may at times overlap. The diagnosis is made endoscopically.
DISCLOSURE OF THE INVENTION The present invention relates to a method of treating non-ulcer dyspepsia in patients suffering from the said non-ulcer dyspepsia, comprising administering to the said patients an effective amount of a pharmaceutically acceptable bismuth salt.
A preferred bismuth compound for the treatment of
non-*αlcer dyspepsia is tripotassium dicitratobismuthate. This is also known as De-Nol (Registered Trade Mark). Other bismuth compounds known for the treatment of ulcer and other diseases may also be used in the present invention. Ideally, the bismuth salt is administered orally for a period of at least four (4) weeks and may be administered alone in an adequate dose or in combination with other antibiotics.
It has further been found that the treatment of non-ulcer dyspepsia with bismuth salt is enhanced by the concurrent administration of an antibiotic.
Particularly suitable antibiotics may be chosen from the classes consisting of β-lactams, such as penicillins; macrolide antibiotics; tetracycline antibiotics and nitro-imidazole sulfones. From within these classes Amoxycillin, Erythromycin, Tetracycline and Tinidazole have been found to be particularly efficacious.
Another aspect of the invention comprises a pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and pharmaceutieally acceptable carrier or diluent.
Preferably the bismuth salt is tripotassium dicitrato-bismuthate.
The most preferable antibiotics are selected from the classes specified above. In particular, the β-lactam antibiotics. Most preferably, the antibiotic is Amoxycillin. The pharmaceutical composition is preferably presented in a form suitable for peroral administration, such as liquid, tablet or capsule form.
BEST MODE OF CARRYING OUT THE INVENTION The invention will now be further described with reference to the following examples. Example 1
27 Patients suffering from non-ulcer dyspepsia associated with C.pyloridis infection were treated with the bismuth salt, tripotassium dicitrato-bismuthate, known under the registered Trade Mark "De-Nol". All patients were administered 107.7mg De-Nol four times daily. Of the 27, 6 were treated with De-Nol alone. Of these it was found that
40% were completely clear of dyspepsia after 1 month and 60% after two months. The remaining patients were treated with combinations of De-Nol and the antibiotics Amoxycillin and Tinidazole. 250mg Amoxycillin was administered four times daily for four weeks and lgm Tinidazole was administered daily for 10 days. The results were 95% clear completely within 4 weeks. Rebiopsy of the completely clear patients, performed 2 weeks after the four week treatment ceased, showed that the patients remained completely clear.
Trials with Amoxycillin alone indicate that Amoxycillin has no appreciable effect in the treatment of dyspepsia. Example 2
The following pharmaceutical formulation is proposed for use in the performance of the present invention: Tablet formulation tripotassium dicitrato-bismuthate 107.7mg amoxycillin 250 mg magnesium.stearate 10 mg maize starch 20 mg
Flavouring substances may be added as required. It will be clear to those skilled in the art that other formulations falling within the scope of the present invention are possible, and that the invention is therefore not restricted to the above formulation.
Claims
1. A method of treating non-ulcer dyspepsia in patients suffering from non-ulcer dyspepsia associated with Campylobacter pyloridis infection, comprising administering to said patients an effective amount of a pharmaceutically acceptable bismuth salt.
2. A method according to claim 1 wherein the bismuth salt is tripotassium dicitrato-bismuthate.
3. A method according to claim 1 wherein the bismuth salt is administered in conjunction with one or more antibiotics.
4. A method according to claim 3 wherein the antibiotics are selected from the β-lactam antibiotics, macrolide anitbiotics, tetracycline antibiotics and nitro-imidazole sul ones.
5. A method according to claim 4 wherein the antibiotics are selected from Amoxycillin, Tinidazole, Erythromycin and Tetracycline.
6. A method according to claim 5 wherein Amoxycillin and Tinidazole are administered in conjunction with the bismuth salt.
7. A method of treating non-ulcer dyspepsia in patients suffering from non-ulcer dyspepsia, substantially as hereinbefore described with reference to the examples.
8. A pharmaceutical composition comprising a pharmaceutically acceptable bismuth salt, an antibiotic and a pharmaceutically acceptable carrier or diluent.
9. A pharmaceutical composition according to claim 8 wherein the bismuth salt is tripotassium dicitrato-bismuthate.
10. A pharmaceutical composition according to either one of claims 8 or 9 wherein the antibiotic is a β-lactam antibiotic.
11. A pharmaceutical formulation according to claim 10 wherein the antibiotic is Amoxycillin.
12. A pharmaceutical formulation substantially as hereinbefore described with reference to the examples.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPH019885 | 1985-04-18 | ||
| AUPH0198 | 1985-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1986005981A1 true WO1986005981A1 (en) | 1986-10-23 |
Family
ID=3771057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/AU1986/000106 WO1986005981A1 (en) | 1985-04-18 | 1986-04-18 | Treatment of non-ulcer dyspepsia with bismuth salts |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0222834A4 (en) |
| JP (1) | JPS62502967A (en) |
| AU (1) | AU590578B2 (en) |
| SG (1) | SG72632A1 (en) |
| WO (1) | WO1986005981A1 (en) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935406A (en) * | 1988-09-20 | 1990-06-19 | Marion Laboratories, Inc. | Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders |
| EP0375068A1 (en) * | 1988-12-23 | 1990-06-27 | Gist-Brocades N.V. | Combining bismuth compounds and tetracyclines |
| EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
| EP0439453A4 (en) * | 1987-10-12 | 1991-02-15 | Borody Thomas J | Improved method for treatment of gastrointestinal disorders. |
| EP0437294A1 (en) * | 1990-01-09 | 1991-07-17 | Yamanouchi Europe B.V. | Oral pharmaceutical compositions in unit dosage form |
| EP0445743A3 (en) * | 1990-03-07 | 1992-10-07 | Pliva Pharm & Chem Works | Complexes and chelates of azithromycin as antiulcer drugs |
| US5192752A (en) * | 1991-01-14 | 1993-03-09 | The Procter & Gamble Company | Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate |
| US5286492A (en) * | 1990-05-03 | 1994-02-15 | Reckitt & Colman Products Limited | Method of treatment of Heliobacter pylori infections with triclosan |
| EP0624373A1 (en) * | 1993-05-11 | 1994-11-17 | Spirig Ag Pharmazeutische Präparate | Pharmaceutical preparation containing bismuth and amoxycillin and its use |
| US5403830A (en) * | 1987-03-09 | 1995-04-04 | The Proctor & Gamble Company | Compositions and methods of treating gastrointestinal disorders |
| US5407688A (en) * | 1987-03-09 | 1995-04-18 | The Procter & Gamble Company | Compositions and methods for treating gastrointestinal disorders |
| WO1996035436A1 (en) * | 1995-05-09 | 1996-11-14 | The Procter & Gamble Company | Compositions comprising bismuth and one or more antimicrobials, for the treatment and prevention of gastrointestinal disorders |
| WO1997020565A1 (en) * | 1995-12-07 | 1997-06-12 | The Procter & Gamble Company | Compositions, containing bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders |
| WO1997020568A1 (en) * | 1995-12-07 | 1997-06-12 | The Procter & Gamble Company | Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders |
| WO1997020567A1 (en) * | 1995-12-07 | 1997-06-12 | The Procter & Gamble Company | Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders |
| AT403656B (en) * | 1991-09-20 | 1998-04-27 | Glaxo Group Ltd | PHARMACEUTICAL COMPOSITION |
| US6258376B1 (en) | 1994-05-02 | 2001-07-10 | Josman Laboratories, Inc. | Method of making chewing gum containing colloidal bismuth subcitrate |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
| US7993682B2 (en) | 2002-03-04 | 2011-08-09 | Thomas Julius Borody | Electrolyte purgative |
| US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
| US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
| US12238494B1 (en) | 2004-07-28 | 2025-02-25 | Ingeniospec, Llc | Head-worn device with connection region |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE135582T1 (en) * | 1985-06-13 | 1996-04-15 | Barry James Marshall | METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISORDERS |
| AU623868B2 (en) * | 1987-10-12 | 1992-05-28 | Capability Services Pty. Limited | Improved method for treatment of gastrointestinal disorders |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6063965A (en) * | 1965-06-25 | 1967-01-05 | Morton W. Scott | Belayed acting compositions |
| FR2029402A1 (en) * | 1969-01-28 | 1970-10-23 | Breive Et Son Jib Labo | Regulation of digestion in gastro intestinal - passage |
| GB1220819A (en) * | 1968-04-24 | 1971-01-27 | Mar Pha Soc D Etude Et D Expl | Improved bismuth salt |
| FR2053002A1 (en) * | 1969-06-21 | 1971-04-16 | Clin Midy | Bismuth slats of alpha methiminobenzyl - penicillin |
| FR2073254A2 (en) * | 1969-12-04 | 1971-10-01 | Dausse Laboratoire | Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders |
| FR2092636A1 (en) * | 1970-06-03 | 1972-01-28 | Griffon Henri | Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders |
| AU438147B2 (en) * | 1968-04-18 | 1973-07-18 | Richard Brown Garland | Antacid composition |
| AU440535B2 (en) * | 1969-12-18 | 1973-09-17 | Export Drugs Company | Antacid compositions |
| AU443154B2 (en) * | 1968-04-05 | 1973-11-28 | Smithkline & French Laboratories | Concentrated liquid antacid compositions |
| AU485660B2 (en) * | 1974-01-18 | 1977-07-28 | Gist-Brocades N.V. | Bismuth containing anti-ulcer compositions in solid form |
| US4153685A (en) * | 1968-11-23 | 1979-05-08 | Schering Corporation | Bismuth complex preparations |
| AU521699B2 (en) * | 1978-02-24 | 1982-04-22 | Novex Talamanyfejlesz To Es | Solid oral pharmaceutical product |
| AU8950382A (en) * | 1981-09-22 | 1983-04-08 | Brocades Pharma B.V. | Bismuth containing composition and method for the preparationthereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4588589A (en) * | 1983-10-13 | 1986-05-13 | Richardson-Vicks Inc. | Antidiarrheal compositions and use thereof |
| ATE79264T1 (en) * | 1985-06-13 | 1992-08-15 | Barry James M D Marshall | USE OF BISMUTH IN THE MANUFACTURE OF MEDICATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS CAUSED BY CAMPYLOBACTER POLYRIDIS. |
| ATE135582T1 (en) * | 1985-06-13 | 1996-04-15 | Barry James Marshall | METHODS AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISORDERS |
-
1986
- 1986-04-18 JP JP61502999A patent/JPS62502967A/en active Pending
- 1986-04-18 SG SG1996004300A patent/SG72632A1/en unknown
- 1986-04-18 AU AU59026/86A patent/AU590578B2/en not_active Expired
- 1986-04-18 EP EP19860903120 patent/EP0222834A4/en not_active Ceased
- 1986-04-18 WO PCT/AU1986/000106 patent/WO1986005981A1/en not_active Application Discontinuation
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6063965A (en) * | 1965-06-25 | 1967-01-05 | Morton W. Scott | Belayed acting compositions |
| AU443154B2 (en) * | 1968-04-05 | 1973-11-28 | Smithkline & French Laboratories | Concentrated liquid antacid compositions |
| AU438147B2 (en) * | 1968-04-18 | 1973-07-18 | Richard Brown Garland | Antacid composition |
| GB1220819A (en) * | 1968-04-24 | 1971-01-27 | Mar Pha Soc D Etude Et D Expl | Improved bismuth salt |
| US4153685A (en) * | 1968-11-23 | 1979-05-08 | Schering Corporation | Bismuth complex preparations |
| FR2029402A1 (en) * | 1969-01-28 | 1970-10-23 | Breive Et Son Jib Labo | Regulation of digestion in gastro intestinal - passage |
| FR2053002A1 (en) * | 1969-06-21 | 1971-04-16 | Clin Midy | Bismuth slats of alpha methiminobenzyl - penicillin |
| FR2073254A2 (en) * | 1969-12-04 | 1971-10-01 | Dausse Laboratoire | Gum guar stabilised suspensions - of insoluble medicaments for treati gastrointestinal disorders |
| AU440535B2 (en) * | 1969-12-18 | 1973-09-17 | Export Drugs Company | Antacid compositions |
| FR2092636A1 (en) * | 1970-06-03 | 1972-01-28 | Griffon Henri | Dried yeast - bismuth subnitrate compositions - for gastrointestinal disorders |
| AU485660B2 (en) * | 1974-01-18 | 1977-07-28 | Gist-Brocades N.V. | Bismuth containing anti-ulcer compositions in solid form |
| AU521699B2 (en) * | 1978-02-24 | 1982-04-22 | Novex Talamanyfejlesz To Es | Solid oral pharmaceutical product |
| AU8950382A (en) * | 1981-09-22 | 1983-04-08 | Brocades Pharma B.V. | Bismuth containing composition and method for the preparationthereof |
Non-Patent Citations (3)
| Title |
|---|
| DATABASE WPI Week 198314, Derwent World Patents Index; AN 1983-34494 * |
| MARTINDALE, 'The Extra Pharmacopoeia', 28th Edition, published 1982, by The Pharmaceutical Press (London), see pages 927 to 930 * |
| See also references of EP0222834A4 * |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5403830A (en) * | 1987-03-09 | 1995-04-04 | The Proctor & Gamble Company | Compositions and methods of treating gastrointestinal disorders |
| US5407688A (en) * | 1987-03-09 | 1995-04-18 | The Procter & Gamble Company | Compositions and methods for treating gastrointestinal disorders |
| EP0439453A4 (en) * | 1987-10-12 | 1991-02-15 | Borody Thomas J | Improved method for treatment of gastrointestinal disorders. |
| JP2733849B2 (en) * | 1987-10-12 | 1998-03-30 | ボロディー，ソーマス・ユリウス | Improved method for treating gastrointestinal disorders |
| US4935406A (en) * | 1988-09-20 | 1990-06-19 | Marion Laboratories, Inc. | Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders |
| EP0375068A1 (en) * | 1988-12-23 | 1990-06-27 | Gist-Brocades N.V. | Combining bismuth compounds and tetracyclines |
| EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
| EP0437294A1 (en) * | 1990-01-09 | 1991-07-17 | Yamanouchi Europe B.V. | Oral pharmaceutical compositions in unit dosage form |
| EP0445743A3 (en) * | 1990-03-07 | 1992-10-07 | Pliva Pharm & Chem Works | Complexes and chelates of azithromycin as antiulcer drugs |
| US5286492A (en) * | 1990-05-03 | 1994-02-15 | Reckitt & Colman Products Limited | Method of treatment of Heliobacter pylori infections with triclosan |
| US5192752A (en) * | 1991-01-14 | 1993-03-09 | The Procter & Gamble Company | Swallowable pharmaceutical compositions containing colloidal bismuth subcitrate |
| AT403656B (en) * | 1991-09-20 | 1998-04-27 | Glaxo Group Ltd | PHARMACEUTICAL COMPOSITION |
| EP0624373A1 (en) * | 1993-05-11 | 1994-11-17 | Spirig Ag Pharmazeutische Präparate | Pharmaceutical preparation containing bismuth and amoxycillin and its use |
| US6616938B2 (en) | 1994-05-02 | 2003-09-09 | Josman Laboratories, Inc. | Method of making chewing gum containing colloidal bismuth subcitrate |
| US6426085B1 (en) | 1994-05-02 | 2002-07-30 | Josman Laboratories Inc. | Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis |
| US6902738B2 (en) | 1994-05-02 | 2005-06-07 | Josman Laboratories, Inc. | Topical oral dosage forms containing bismuth compounds |
| US6258376B1 (en) | 1994-05-02 | 2001-07-10 | Josman Laboratories, Inc. | Method of making chewing gum containing colloidal bismuth subcitrate |
| US6372784B1 (en) | 1995-02-07 | 2002-04-16 | Josman Laboratories, Inc. | Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds |
| US6379651B1 (en) | 1995-02-07 | 2002-04-30 | Josman Laboratories | Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases |
| WO1996035436A1 (en) * | 1995-05-09 | 1996-11-14 | The Procter & Gamble Company | Compositions comprising bismuth and one or more antimicrobials, for the treatment and prevention of gastrointestinal disorders |
| WO1997020565A1 (en) * | 1995-12-07 | 1997-06-12 | The Procter & Gamble Company | Compositions, containing bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders |
| WO1997020567A1 (en) * | 1995-12-07 | 1997-06-12 | The Procter & Gamble Company | Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders |
| WO1997020568A1 (en) * | 1995-12-07 | 1997-06-12 | The Procter & Gamble Company | Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders |
| US7993682B2 (en) | 2002-03-04 | 2011-08-09 | Thomas Julius Borody | Electrolyte purgative |
| US8679549B2 (en) | 2002-03-04 | 2014-03-25 | Thomas Julius Borody | Electrolyte purgative |
| US12238494B1 (en) | 2004-07-28 | 2025-02-25 | Ingeniospec, Llc | Head-worn device with connection region |
| US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
| US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
Also Published As
| Publication number | Publication date |
|---|---|
| AU590578B2 (en) | 1989-11-09 |
| AU5902686A (en) | 1986-11-05 |
| JPS62502967A (en) | 1987-11-26 |
| SG72632A1 (en) | 2000-05-23 |
| EP0222834A1 (en) | 1987-05-27 |
| EP0222834A4 (en) | 1989-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU590578B2 (en) | Treatment of non-ulcer dyspepsia with bismuth salts | |
| US5256684A (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| CA1277232C (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
| US5601848A (en) | Methods for the treatment of gastrointestinal disorders | |
| US5629297A (en) | Medicament for treating gastrointestinal disorders | |
| CA2344308C (en) | Taurolidine and/or taurultam against infectious ulcer or gastritis | |
| EP0544760B1 (en) | Pharmaceutical compositions containing 5-difluoromethoxy-2- (3,4-dimethoxy-2-pyridyl) methylsulfinyl] benzimidazole and an anti-helicobacter agent for the treatment of gastrointestinal disorders | |
| Hewitt | The penicillins: a review of strategy and tactics | |
| US4959384A (en) | Use of nitrofurantoin for the treatment and prophylaxis of gastrointestinal disorders | |
| KR100550839B1 (en) | Antimicrobial | |
| Labenz et al. | High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease | |
| EP0591446B1 (en) | Method for treating helicobacter pylori gastritis | |
| Glupczynski | In vitro susceptibility of Helicobacter pylori to antibiotics and bismuth salts and the importance of acquired resistance to antibiotics in treatment failures of H. pylori infection | |
| RU2076708C1 (en) | Pharmaceutical composition and method of gastroenteric sickness treatment and prophylaxis | |
| RU2187318C2 (en) | Method of healing chronic gastritis and duodenum ulcer disease | |
| EP0865286B1 (en) | Compositions, comprising bismuth and one or more antimicrobials, for the prevention and treatment of gastrointestinal disorders | |
| Reinfection | C. O'MORAIN | |
| O’Morain | How to eradicate Helicobacter pylori and prevent reinfection | |
| JPH0920668A (en) | Antibacterial agent for helicobacter pylori as slightly aerobic gram-negative bacillus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1986903120 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1986903120 Country of ref document: EP |
|
| WWR | Wipo information: refused in national office |
Ref document number: 1986903120 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1986903120 Country of ref document: EP |